Company profile for MolGenie

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MolGenie is using and developing compound design technologies aiming at drug-like and selective small molecules that exhibit a clear structure-activity relationship and have the promise of good tolerability and oral bioavailability. MolGenie has been formed in 2021 to use its network of experts in drug discovery and development to advance interesting new therapeutic agents towards IND applications.The company was started in St...
MolGenie is using and developing compound design technologies aiming at drug-like and selective small molecules that exhibit a clear structure-activity relationship and have the promise of good tolerability and oral bioavailability. MolGenie has been formed in 2021 to use its network of experts in drug discovery and development to advance interesting new therapeutic agents towards IND applications.The company was started in Stuttgart, Germany, on February 23, 2021. It offers drug discovery services and develops its own intellectual property for selected biological targets and diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Felix-Dahn-Str. 4 70597 Stuttgart
Telephone
Telephone
+49-711-99333338
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/contents/view_breaking-news/2021-12-07/anixa-biosciences-molgenie-find-covid-compounds-effective-against-omicron/?widget=listSection

CONTRACTPHARMA
08 Dec 2021

https://www.biospace.com/article/releases/anixa-biosciences-and-molgenie-announce-that-their-covid-19-compounds-are-expected-to-be-effective-against-the-omicron-variant/?s=71

BIOSPACE
07 Dec 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty